Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (NASDAQ: OM) is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, and its news flow reflects both business performance and developments in kidney care. Company press releases regularly describe Outset as pioneering a first-of-its-kind technology designed to reduce the cost and complexity of dialysis across hospital and home settings.
News updates for OM commonly include quarterly financial results, where Outset reports product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and cash balances. These releases may also include revised or updated annual revenue guidance and commentary on progress toward financial objectives.
Investors and clinicians following Outset Medical can also expect clinical and research news. The company has highlighted data from large numbers of Tablo treatments across hundreds of facilities, as well as multi-year results from hospitals that have insourced dialysis service lines using Tablo. Such announcements focus on clinical outcomes, operational metrics, and the implications of insourced dialysis models for acute-care facilities.
Outset’s news stream further covers strategic and corporate developments, such as board appointments, the creation of clinical leadership roles, and collaborations with dialysis providers to expand access to home hemodialysis using Tablo. The company also announces presentations at major healthcare and investor conferences, where management discusses its technology, business strategy, and financial performance.
This OM news page aggregates these releases so readers can follow Outset Medical’s earnings reports, clinical evidence updates, collaborations, and corporate milestones in one place.
Outset Medical, Inc. (Nasdaq: OM) reported third-quarter 2020 net revenue of $13.8 million, marking a 423% increase from $2.6 million in Q3 2019. The company launched the Tablo device for home use and secured a second contract with the U.S. Health Department. However, net loss expanded to $42.3 million or $3.44 per share, compared to a loss of $16.7 million in the prior year. Operating expenses rose to $35.6 million, driven by increased R&D and marketing costs. Cash reserves totaled $377.5 million post-IPO, reflecting robust liquidity.
Outset Medical, Inc. (Nasdaq: OM) has appointed Steve Williamson as Chief Commercial Officer to lead its commercial and service organizations, enhancing adoption of the Tablo Hemodialysis System. Under Williamson's leadership, the company experiences meaningful growth in health systems and received FDA clearance for home use. With over two decades in the medical technology field, including significant revenue growth at BD, Williamson aims to reduce dialysis costs and complexity, improving patient experiences.
Outset Medical, Inc. (Nasdaq: OM) plans to release its third-quarter 2020 financial results on November 11, 2020, after the market closes. Following the release, CEO Leslie Trigg and CFO Rebecca Chambers will host a conference call at 2:00 PM PT (5:00 PM ET) to discuss the results. Outset is known for its innovative Tablo Hemodialysis System, designed to simplify dialysis processes and reduce costs. This technology has been FDA cleared for both hospital and home use, streamlining patient care significantly.